|
|
|
28.02.26 - 15:48
|
Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting (GlobeNewswire EN)
|
|
|
WALTHAM, Mass. and BOULDER, Colo., Feb. 28, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced additional clinical results from the pivotal SUMMIT trial with bezuclastinib in patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting. As previously reported, bezuclastinib demonstrated clinically meaningful and highly statistically significant improvements across the primary and all key secondary endpoints. New results highlight the deepening of clinical benefit over longer treatment duration, the benefit of bezuclastinib in populations with high unmet need, and bezuclastinib's impact on bone mineral density as additional evidence of disease modification....
|
|
|
28.02.26 - 15:42
|
Goliath Resources Proposes to Extend Term of Warrants Held by McEwen Inc. (GlobeNewswire EN)
|
|
|
TORONTO, Feb. 28, 2026 (GLOBE NEWSWIRE) -- Goliath Resources Limited (TSX-V: GOT) (OTCQX: GOTRF) (FSE: B4IF) (“Goliath” or the “Company”) announces that it has applied to the TSX Venture Exchange (the “TSXV”) to extend the term of an aggregate of 2,590,673 common share purchase warrants of the Company (the “Warrants”), with each Warrant being exercisable to acquire one common share of the Company (each a “Warrant Share”) at a price of $2.50 per Warrant Share. As disclosed by the Company in a news release dated March 10, 2025, the Warrants were issued by the Company on March 10, 2025 in connection with a $10,000,000 strategic non-brokered private placement of 5,181,347 units of the Company (“Units”) to McEwen Inc. (NYSE: MUX) (TSX: MUX) (“McEwen”), an arm's length party to the Company, at a deemed price of C$1.93 per Unit, in exchange for the issuance to the Company of an aggregate of 868,056 shares of common stock of McEwen (“McEwen Shares”) at a deemed price of C$11.52 ...
|
|
|
|
|
|
|
|
|
28.02.26 - 04:57
|
SQM Reports Earnings for the Twelve Months Ended December 31, 2025 (GlobeNewswire EN)
|
|
|
SANTIAGO, Chile, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Sociedad Química y Minera de Chile S.A. (SQM) (NYSE: SQM; Santiago Stock Exchange: SQM-B, SQM-A) reported today net income for the twelve months ended December 31, 2025, of US$588.1 million or US$2.06 per share, compared to a loss of US$(404.4) million or US$(1.42) per share reported for the same period last year....
|
|
|
|
|
|
|
28.02.26 - 01:03
|
YY Group Announces US$20 Million At-The-Market Offering Facility (GlobeNewswire EN)
|
|
|
SINGAPORE, Feb. 27, 2026 (GLOBE NEWSWIRE) -- YY Group Holding Limited (NASDAQ: YYGH) (“YY Group” or the “Company”), a global leader in on-demand workforce solutions and integrated facilities management (IFM), today announced that it has entered into an At The Market Sales Agreement (the "ATM Agreement") with Spartan Capital Securities, LLC ("Spartan") and Wilson-Davis & Co., Inc. (“WDCO,” and together with Spartan, the “Sales Agents”), pursuant to which the Company may offer and sell, from time to time, up to US$20,000,000 of its Class A Ordinary Shares through the Sales Agents, acting as sales agents....
|
|
|
28.02.26 - 00:27
|
Brookfield Property Partners Completes 2025 Annual Filings (GlobeNewswire EN)
|
|
|
BROOKFIELD NEWS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Brookfield Property Partners announced today that it has filed its 2025 annual report on Form 20-F, including its audited financial statements for the year ended December 31, 2025, with the SEC on EDGAR as well as with the Canadian securities authorities on SEDAR+. These documents are also available at bpy.brookfield.com....
|
|
|
28.02.26 - 00:00
|
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older (GlobeNewswire EN)
|
|
|
COPENHAGEN, Denmark, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has granted approval under the FDA's Accelerated Approval Program for YUVIWEL® (navepegritide; developed as TransCon® CNP), the first and only once-weekly treatment indicated to increase linear growth in children 2 years of age and older with achondroplasia with open epiphyses and the only one to provide continuous systemic exposure to CNP over the weekly dosing interval. Continued approval for this indication, which was based on an improvement in annualized growth velocity (AGV), may be contingent upon verification and description of clinical benefit in confirmatory trial(s)....
|
|
|
27.02.26 - 23:33
|
Pulsar Helium Announces Closing of Fundraise (GlobeNewswire EN)
|
|
|
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR TO BE TRANSMITTED, DISTRIBUTED TO, OR SENT BY, ANY NATIONAL OR RESIDENT OR CITIZEN OF ANY SUCH COUNTRIES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION MAY CONTRAVENE LOCAL SECURITIES LAWS OR REGULATIONS....
|
|
|
|
|
27.02.26 - 23:33
|
OpGen, Inc. (OTC: OPGN) Announces Name Change to CapForce Inc. (GlobeNewswire EN)
|
|
|
CLARKSBURG, Md., Feb. 27, 2026 (GLOBE NEWSWIRE) -- OpGen, Inc. (OTC: OPGN) today announced that it is changing its name to CapForce Inc., effective today. OpGen changed its name to CapForce Inc. in order to reflect the repositioning of the Company's business to the digital investment banking and financial technology sectors. The name “CapForce” represents the “Force of Capital,” symbolizing the Company's conviction as a next-generation category-defining fintech-powered investment bank that harnesses the intrinsic force of capital, through capital markets as the empowerment medium, to empower global mid-sized high growth companies to grow beyond the small-cap universe and punch above their weight to enter the mid-cap or even large-cap universe. In connection with the name change, the Company expects to change its ticker symbol to “CFOR.”...
|
|
|
27.02.26 - 23:30
|
Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
ATLANTA, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today it has granted to two new non-executive employees who began their employment with Femasys in February 2026 options to purchase 185,000 shares of Femasys common stock....
|
|
|
|
|
27.02.26 - 23:18
|
Prime Drink Group Announces Management Change (GlobeNewswire EN)
|
|
|
MONTRÉAL, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) is pleased to announce the appointment of Germain Turpin as Interim President and Chief Executive Officer of the Company. Mr. Turpin succeeds Alexandre Côté, who will step down from his position on February 28, 2026, while remaining on the Board of Directors and retaining responsibility for special projects....
|
|
|
|
|
|
|
27.02.26 - 23:03
|
Refined Energy Corp. Announces Further Extension to Marketing Program (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Refined Energy Corp. (CSE: RUU | OTC: RRUUF | FRA: CWA0) ("Refined” or the "Company") is pleased to announce, further to its news releases on October 31, 2025, December 12, 2025, January 2, 2026 and January 15, 2026, that it is extending its engagement of RMK Marketing Inc. (address: 541 Lana Terrace, Mississauga, Ontario, Canada L5A 3B2, email: roberto@rmkmarketing.ca) (“RMK”) for marketing services for an additional anticipated period of 90 days commencing on or about March 2nd, 2026 (provided that the term of the marketing services may be extended or shortened at the discretion of management and the board of directors of the Company depending on, amongst other things, the efficiency of the marketing services)....
|
|